Abstract
Introduction 65
Digestion, i.e. the breakdown and mixing of food with secretions, nutrient digestion 66 and absorption, propulsion of the contents throughout the gut and, finally, the expulsion 67 of undigested material, requires a vast repertoire of highly integrated regulatory 68 mechanisms. These are finely tuned by a variety of cell types, including endocrine cells 69 (distributed throughout the gastrointestinal mucosa), smooth muscle cells (final effectors 70 of contractility and/or relaxation), interstitial cells of Cajal (ICC) (pace-makers of gut 71 motility and regulators of neuro-muscular transmission) and neurons of both intrinsic 72 (enteric) and extrinsic (sympathetic and parasympathetic) origin (50). The neural network 73 of the digestive system, including the enteric nervous system (ENS), exerts a prominent 74 regulatory role. From a structural standpoint, the ENS contains about 100 to 500 million 75 neuronal cell bodies organized in two major ganglionated plexuses (i.e., myenteric and 76 submucosal), neural processes connecting the ganglia among them, and nerve fibers 77 targeting many different effector cells. In addition to neurons, enteric glial cells (EGCs) 78
were recently identified as key players in the ENS. EGCs, which form the largest cell 79 population of the ENS, have long been thought to exert a mere mechanical property by 80 supporting neurons (hence the ancient Greek name "glia"' which means "glue" -a term 81 coined by the German pathologist Rudolf Virchow). Recent evidence, however, indicates 82 that these cells exhibit a number of functions, ranging from neurotransmission to enteric 83 neuronal maintenance and survival. As a result, damage to the enteric glia may elicit 84 neurodegenerative processes which are thought to contribute to GI dysfunction (37) . 85
Currently, only glia ablation models indirectly supported the concept of an enteric 86 neuroprotective role exerted by EGCs. However, very recent evidence unravelled a number 87 of EGC mediated bioactive messengers exerting neuroprotective effects (1) (2) 10 (20, 32, 37) . The EGCs outnumber neurons with a 115 ratio ranging from 1.3 to 1.9 and from 5.9 to 7.0 in the human submucosal and myenteric 116 plexuses, respectively (23) and surround the neuronal cell bodies tightly (i.e., the 117 remaining extracellular space consists of narrow 20 nm gaps) (20) . As in the blood-brain 118 barrier, ECGs possess several flat endfeet (or cytoplasmic expansions) which form a blood-119 enteric barrier protecting the enteric neurons from potentially harmful extraganglionic 120 substances (41). Compared with other peripheral glial cells (e.g., Schwann cells), EGCs 121 differ in that they do not form basal laminae and they ensheath nerve bundles and not 122 individual axons (6). 123
Available immunohistochemical markers for EGC labeling in the adult gut include 124 GFAP, S100β and Sox8/9/10, the first two being the most frequently used (23, 37) ( Figure  125 1). In the gut, GFAP is considered a specific mature EGC marker (25), although it does not 126 reliably distinguish between enteric and extrinsic glia, since GFAP is also expressed in non-127 myelinating Schwann cells (26). S100 is a Ca 2+ binding protein stored in the cytoplasm and 128 / or in the nucleus of both nervous and non-nervous tissue where it exerts diffusible 129 neurotrophic properties (52). Although there are several S100 isoforms in the nervous 130 tissue, EGCs constitutively and specifically express only the S100β (37). The nuclear Sox 131 transcription factor family (Sox8/9/10) represents one of the latest markers proposed for 132 EGC identification (49). Sox8/9 expression has been demonstrated in neural crest cells and 133 in immature glial cells, while Sox10 appears to be restricted to EGCs in the mature ENS 134 (51). Thus, using antibodies targeting Sox8/9/10, it is possible to label EGC nuclei and 135 thereby perform precise and quantitative analysis of EGC density (21, 23) . 136
EGCs have long been thought to be a scaffold for neurons with no other 137
properties. This old view has been thoroughly changed by recent data showing that 138
EGCs are involved in many crucial tasks, such as synthesis of neurotransmitter7 precursors, uptake and degradation of neuroligands (i.e., detoxification of glutamate 140 and gamma aminobutyric acid), and expression of neurotransmitter receptors, thereby 141 contributing to neuron-glia cross-talk and neurotransmission. Furthermore, EGCs exhibit 142 immunological properties (16, 33, (37) (38) , participate in epithelial barrier functions (11, 143 32, 40, 43, 45-46) and evoke neuroprotection (19, 28, 39) , the latter being the focus of 144 this review. 145
146

EGC Neuroprotective Functions: Lessons from Enteric Glia Ablation Models 147
Recent research has addressed the protective role of EGCs towards enteric neurons. 148
This property has been tested by using EGC ablation strategies in vivo or in vitro. oxidative stress (1, 40). Furthermore, EGC protective effects could also be due to their 253 detoxification properties as they are able to take up glutamate or γ-aminobutyric acid from 254 an extracellular milieu by means of L-glutamate transporter (42) or γ-aminobutyric acid 255 transporter 2 (19), respectively. 256
Besides GSH, glial cell line derived neurotrophic factor (GDNF) has been shown to 257 play a major role in enteric neuroprotection. In particular, the loss of nitrergic neurons as 258 a result of streptozotocin-induced diabetes was attenuated in GFAP-GDNF transgenic mice 259 as compared to nontransgenic controls. GDNF has consistently been shown to prevent 260 enteric neuronal apoptosis induced by hyperglycemia through a mechanism involving 261 decreased PKB phosphorylation (3). GDNF has also been shown to protect enteric neurons 262 in vitro and participate in Western diet induced neuroprotection in the ENS. Interestingly, 263 nutritional modulation of GDNF production in the gut could be used as an interesting 264 neuroprotective strategy (10). 265
266
More recently, EGCs have been demonstrated to produce lipid derived mediators, 267 such as 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) (5), which exerts a crucial role in 268 intestinal epithelial barrier maintenance. EGC derived 15d-PGJ2 was also shown to exert 269 neuroprotection in the ENS through an increase in nuclear erythroid 2-related factor 2 270 expression and leading to an increase in intracellular neuronal glutathione production (2). 271 A summary of these EGC-mediated neuroprotective mechanisms has been illustrated in 272 
EGC Abnormalities in the Clinical Setting 279
In humans, a substantial loss of EGCs has been described in patients with various 280 functional (8) and/or inflammatory GI diseases (9, 13). However, it still remains largely 281 unclear whether these changes are currently directly responsible for GI 282 dysfunctions/symptoms or whether they are the consequences of the disease. 283
Slow transit constipation (STC) is a term usually applied to define a subgroup of 284 patients with markedly delayed gut transit refractory to various therapeutic measures; 285 some selected cases of STC (the most severe ones with colonic inertia) can be referred to 286 surgery for total colectomy. Bassotti et al. (9) investigated a cohort of 26 severe and 287 intractable STC patients and found that, compared to controls, the histopathological 288 analysis of colonic full thickness specimens revealed a wide array of ENS abnormalities 289 characterized by a quantitative loss of enteric neurons (in both myenteric and submucosal 290 plexuses), ICCs, and S100β labeled EGCs. Because of the well known properties exerted 291 by EGCs on enteric neurons (previously discussed in this review), the authors were the 292 first to imply a pathogenetic role of glial cell alteration in STC. This exciting possibility led 293 them to indicate the existence of a "gliopathy" (in addition to a "neuropathy") playing a 294 role in STC. Whether the actual impairment of EGCs is likely to have an impact on the 295 enteric nerves, however, awaits further confirmatory evidence not only for STC, but also 296 for other functional GI diseases. In particular, whether EGC changes precede neuronal 297 degeneration and loss and how this damage could occur remain unsettled. Other results 298
showing EGC abnormalities with or without ICC depletion have been reported by Bassotti's 299 group in patients with diverticular disease (7) and megacolon (either idiopathic or 300 secondary to Chagas disease) (24). The effect of the EGC abnormalities on enteric 301 neurons under these conditions is still debated. 302
Concerning IBD patients with ulcerative colitis (UC), Cirillo et al. (13) 
demonstrated that 303
EGCs directly participate in chronic mucosal inflammation. In particular, in the rectal 304 mucosa of UC patients there was an increased S100β mRNA expression, immunoreactivity 305 and secretion which led to enhanced nitric oxide (NO) production through the specific 306 stimulation of inducible NOS (iNOS). Since UC is characterized by abnormal mucosal NO 307 production and associated pro-inflammatory cytokines, it is tempting to speculate that 308 these mediators might affect enteric neuron function and thus gut physiology. 309
Furthermore, data obtained with an ex vivo human model of infectious disease (i.e., release of 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) (2) which increases nuclear 562 erythroid 2-related factor 2 (Nrf2) and of catalytic subunit of glutamate cysteine ligase 563 (GCLc) expression and thereby enhancing GSH levels in enteric neurons. Thus, EGCs play 564 a central role by acting directly and indirectly as regulators of GSH in enteric neurons. 565
EGCs can also release GDNF, a well known mediator of enteric neuroprotection by 566 reducing apoptosis mediated by phosphatidylinositol-3-kinase / alpha serine / threonine-567 protein kinase (PI3K / Akt) (3). EGCs can also hamper excitotoxicity by removing GABA 568 and glutamate (Glu) from the extracellular milieu via different transporters (i.e. γ-569 aminobutyric acid transporter 2, GAT2; L-glutamate transporter, Glt1) (19, 42) . Thereafter, 570 glutamine synthetase (GS), largely expressed in EGCs, converts Glu into glutamine (Gln), 571
